A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa [Estudio de fase II de BEZ235 en monoterapia administrado por via oral en pacientes con PEComa maligno irresecable o metastasico]

Trial Profile

A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa [Estudio de fase II de BEZ235 en monoterapia administrado por via oral en pacientes con PEComa maligno irresecable o metastasico]

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 03 Feb 2014

At a glance

  • Drugs Dactolisib (Primary)
  • Indications Perivascular epithelioid cell tumours
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Aug 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
    • 09 Jan 2013 New source identified and integrated: European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top